An Open-label Bosutinib Treatment Extension Study For Subjects With Chronic Myeloid Leukemia (Cml) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Pfizer
- 30 May 2017 Planned number of patients changed from 287 to 300.
- 28 Feb 2017 Planned End Date changed from 1 Mar 2020 to 1 Apr 2020.
- 28 Feb 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Apr 2020.